Nuvectra Corporation

Nuvectra — Investor Presentation (November 2016)

21 slides from Nuvectra's investor presentation, Nov 16, 2016

  1. Slide 1: Investor Presentation: New Directions in Neurostimulation

    NUVECTRA Investor Presentation New Directions in Neurostimulation November 2016

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Forward Looking Statements This presentation contains "forward-looking statements,” including statements we make regarding the outlook for Nuvectra as an independent publicly-traded company. Forward-looking statements are based only on our current beliefs, expectations and assumptio

  3. Slide 3: Nuvectra Spin Off

    Nuvectra Spin Off Greatbatch ‘The Spin’ 2009-2015 March 14% 2016 $75M Funding Greatbatch Funded R&D $45M2) Phase Design & Development Commercialization MARKET RESEARCH REGULATORY COMPANY Biber CLINICAL SALES & CONCEPT | VERIFICATION FORMATION & VALIDATION MARKETING STRATEGY QUALITY QiG NUVECTRA (1)

  4. Slide 4: Nuvectra Positioned for Success

    Nuvectra Positioned for Success Nel ff 7] Large & Growing Platform Algovita SCS Focused on Target Markets Technology System Growth ~$2.8B *Spinal Cord + Expansive +Powerful IPG *Build world class Stimulation (SCS) IP portfolio *Stretchable leads distribution team * Sacral Nerve +Access to multiple «

  5. Slide 5: Neurostimulation Targeted Market Opportunity

    Neurostimulation Targeted Market Opportunity ~$2.8B Target Market ~7.5% CAGR through 2018 SNS Market) DBS Market) ail 42% 4 96% Chronic Pain Bladder & Bowel Control Movement Disorders ~$1.7B ~$570M ~$600M ~6% CAGR ~9.5% CAGR ~10% CAGR oan $750 $725 sig $19 $20 $690 $650 $1.7 $630 $600 $1.6 $520 $570

  6. Slide 6: Platform Designed for Multiple Indications

    Platform Designed for Multiple Indications Expansive Proprietary IP Portfolio 104 Issued 48 Pending Physician & Patient Programmers Proprietary Processors NUVECTRA

  7. Slide 7: Building a Neurostimulation Company

    Building a Neurostimulation Company scs IB Product Planning (Market Research, Clinician Partners, Competitive Landscape) [BB Product Design & Development {0 Regulatory submissions {BB Regulatory Approvals & Commercialization EER cE Mark approval for algovita received June 2014 FDA Approval of the PM

  8. Slide 8: SCS — Our First Opportunity

    SCS — Our First Opportunity Chronic Pain\".2) + 1.5B WW suffer from chronic pain Chronic pain is a + 100M Americans suffer from severe and chronic pain significant medical, economic and social problem + $300B annual healthcare spend in the US * Chronic pain sufferers are also affected with depressio

  9. Slide 9: World Renowned SCS Physician Advisors

    World Renowned SCS Physician Advisors Giancarlo Barolat, MD | Chief Medical Advisor + Professor of Neurosurgery, Thomas Jefferson University, Philadelphia, PA (1985-2005) + Director, Barolat Neuroscience Center at Presbyterian St. Luke’s Hospital, Denver, CO (2005-present) + Director of Barolat Neur

  10. Slide 10: Experienced Leadership Team

    Experienced Leadership Team Scott Drees | CEO & Director bs + QIG Group , CEO & Founding Partner if + Founding Division President, Advanced Neuromodulation Systems Inc. (ANSI) + Prior experience: St. Jude Medical, Boston Scientific, Johnson & Johnson + 35 yrs. implantable medical devices experience;

  11. Slide 11: Algovita SCS System

    Algovita SCS System Powerful Versatile Usable NUVECTRA

  12. Slide 12: Powerful IPG Therapy Delivery

    Powerful IPG Therapy Delivery + 24 channels + Large battery capacity + Broad parametric ranges + Bi-directional recharge + MICS wireless telemetry + Embedded program memory Proprietary Stimulation & Power Processors *: ) Configuration 2x8 2x8 a8 2x8 # of Channels 24 16 16 32 16 # of Power Sources 24

  13. Slide 13: A New Generation of Lead Design

    A New Generation of Lead Design 7 Algovita . Market Opportunities + Increase spinal coverage + Lead elongation + Reduce lead migration (13%) COIL DESIGN UNCONSTRAINED INDEPENDENT COIL IN COIL DESIGN COIL STRUCTURE STRAIGHT WIRE STRAIGHT WIRE DUAL COIL STRUCTURE 4-Electrode Leads 8-Electrode Leads 8

  14. Slide 14: Simplifying Programming Complexity

    Simplifying Programming Complexity Patient Clinician + Wireless telemetry + Colored touchscreens * Highly intuitive + Patient interactive programming + Discreet & portable patient control Competitive Devices") Patient Controllers PatientIPG Rechargers NUVECTRA

  15. Slide 15: Algorithm for SCS Success

    Algorithm for SCS Success 1. Intra-operative: Traditional Placement A. Place leads B. Confirm lead position C. Close 2. Post-operative: Patient Interactive Programming & Optimization Mm ta A. Patient identifies B. Optimize stimulation C. Provide activity optimal contacts program options 3. Daily Usa

  16. Slide 16: U.S. Commercialization

    U.S. Commercialization Hire Proven Team of * Build world class team Sales Talent + Foster high achieving culture Sales management, national * Focus on SCS market share account coverage, direct reps, + Initiate clinical studies sales agents, clinical specialists + Establish technology leadership + 42

  17. Slide 17: Medical Advisory Board

    Medical Advisory Board NUVECTRA plas M. Levy, MD, PhD | Chairman Board-certified neurological surgeon + Member of Executive Board of Directors of the International Neuromodulation Society (“INS”) + 25+ years experience in neurosurgery, including serving in leadership and academic positions at presti

  18. Slide 18: SNS — Our Second Opportunity

    SNS — Our Second Opportunity Indications System + Urinary Incontinence ey Overactive Bladder (OAB): Urgency Incontinence & Urgency Frequency Urinary Retention + Fecal Incontinence Pulse ‘Generator Lead Sacral Nerves Bladder Market Opportunity * 20+ yrs. proven efficacy + Established reimbursement +

  19. Slide 19: Strategic Development Agreement

    Strategic Development Agreement Relationship Overview alev + Development agreement through 2017 + Nuvectra to license platform of IPG and programmers to Aleva for royalties + Aleva provides MEMS technology with directSTIM directional DBS lead + Field of use: DBS for Parkinson's Disease (PD) + Aleva

  20. Slide 20: NeuroNexus

    4} NeuroNexus Designs, develops and manufactures leading edge neuroscience technology and devices for clinical research markets Neurostim Penetrating Deep Brain Surface Groce | Drug Chemical Nerve Delivery Sensing MRI Optogenetics Smartbox™ High-performance 256 channel recording system Provides earl

  21. Slide 21: Nuvectra Positioned for Success

    Nuvectra Positioned for Success Nel ff 7] Large & Growing Platform Algovita SCS Focused on Target Markets Technology System Growth ~$2.8B *Spinal Cord + Expansive +Powerful IPG *Build world class Stimulation (SCS) IP portfolio *Stretchable leads distribution team * Sacral Nerve +Access to multiple «

Nuvectra — Investor Presentation (November 2016) on 6ix